Tumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancer.

by Lynda Mezil, Carole Berruyer-Pouyet, Olivier Cabaud, Emmanuelle Josselin, Sébastien Combes, Jean-Michel Brunel, Patrice Viens, Yves Collette, Daniel Birnbaum, Marc Lopez
Published 2012-01-01